(3-methyl-[1,2]oxazolo[5,4-b]pyridin-5-yl)-(2-pyridin-4-ylpyrrolidin-1-yl)methanone
C17H16N4O2 — CID 51076263
Data last refreshed: (MolForge compound catalog, from PubChem)
About (3-methyl-[1,2]oxazolo[5,4-b]pyridin-5-yl)-(2-pyridin-4-ylpyrrolidin-1-yl)methanone
(3-methyl-[1,2]oxazolo[5,4-b]pyridin-5-yl)-(2-pyridin-4-ylpyrrolidin-1-yl)methanone (PubChem CID 51076263) has the molecular formula C17H16N4O2 and a molecular weight of 308.34 g/mol. Its IUPAC name is (3-methyl-[1,2]oxazolo[5,4-b]pyridin-5-yl)-(2-pyridin-4-ylpyrrolidin-1-yl)methanone.
Molecular Properties
| Compound Name | (3-methyl-[1,2]oxazolo[5,4-b]pyridin-5-yl)-(2-pyridin-4-ylpyrrolidin-1-yl)methanone |
|---|---|
| PubChem CID | 51076263 |
| Molecular Formula | C17H16N4O2 |
| Molecular Weight | 308.34 g/mol |
| Exact Mass | 308.13 |
| IUPAC Name | (3-methyl-[1,2]oxazolo[5,4-b]pyridin-5-yl)-(2-pyridin-4-ylpyrrolidin-1-yl)methanone |
| SMILES | Cc1noc2ncc(C(=O)N3CCCC3c3ccncc3)cc12 |
| InChI | InChI=1S/C17H16N4O2/c1-11-14-9-13(10-19-16(14)23-20-11)17(22)21-8-2-3-15(21)12-4-6-18-7-5-12/h4-7,9-10,15H,2-3,8H2,1H3 |
| InChIKey | LIWTTWLCTUZWFB-UHFFFAOYSA-N |
| XLogP | 2.90 |
| TPSA | 72.12 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 23 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 308.34 |
| LogP ≤ 5 | 2.90 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 51076263 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.